<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03116685</url>
  </required_header>
  <id_info>
    <org_study_id>OC5-DB-02</org_study_id>
    <nct_id>NCT03116685</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria</brief_title>
  <official_title>A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OxThera</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OxThera</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of OC5 in patients with PH.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 9, 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in plasma oxalate concentration after 52 weeks of treatment</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in total plasma oxalate concentration after 52 weeks of treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Primary Hyperoxaluria</condition>
  <arm_group>
    <arm_group_label>Oxabact OC5 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxabact OC5 - Oxalobacter formigenes HC-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Oxabact OC5 - Oxalobacter formigenes HC-1</intervention_name>
    <description>Active study drug</description>
    <arm_group_label>Oxabact OC5 capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent (as applicable for the age of the subject)

          2. A diagnosis of PH (as determined by standard diagnostic methods).

          3. eGFR &lt; 90 ml/min/1.73 m2. The Schwartz formula will be used to estimate GFR for
             children (age below 18), and CKD-EPI formula will be used for adults (age 18 or
             above).

          4. Plasma oxalate concentration ≥10 μmol/L in total plasma oxalate.

          5. Male or female patients ≥ 2 years of age.

          6. Patients receiving vitamin B6 must be receiving a stable dose for at least 3 months
             prior to screening and must not change the dose during the study. Patients not
             receiving vitamin B6 at study entry must be willing to refrain from initiating
             pyridoxine during study participation.

        Exclusion Criteria:

          1. Inability to swallow size 4 capsules.

          2. Subjects that have undergone transplantation (solid organ or bone marrow).

          3. Patients requiring dialysis or at immediate risk for kidney failure or expected to be
             in need of dialysis during the study period.

          4. The existence of secondary hyperoxaluria, e.g. hyperoxaluria due to bariatric surgery
             or chronic gastrointestinal diseases such as cystic fibrosis, chronic inflammatory
             bowel disease and short-bowel syndrome.

          5. Use of antibiotics to which O. formigenes is sensitive. (This includes current
             antibiotic use, or antibiotics use within 14 days of initiating study medication).

          6. Current treatment with a separate ascorbic acid preparation.

          7. Pregnant women (or women who are planning to become pregnant) or lactating women.

          8. Women of childbearing potential who are not using adequate contraceptive precautions.
             Please see section 7.3 regarding requirements for contraception.

          9. Presence of a medical condition that the Investigator considers likely to make the
             subject susceptible to adverse effect of study treatment or unable to follow study
             procedures or any condition that is likely to interfere with the study drug mechanism
             of action (such as abnormal GI function).

         10. Participation in any interventional study of another investigational product,
             biologic, device, or other agent within 60 days prior to the first dose of OC5 or not
             willing to forego other forms of investigational treatment during this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderbilt University Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn, Dept of Pediatric Nephrology</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hédi Chaker University Hospital</name>
      <address>
        <city>Sfax</city>
        <zip>3000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahloul University Hospital</name>
      <address>
        <city>Sousse</city>
        <zip>4054</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles Nicolle University Hospital</name>
      <address>
        <city>Tunis</city>
        <zip>1008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham Children's Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Tunisia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2017</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

